Details for New Drug Application (NDA): 206815

NDA 206815 describes SODIUM POLYSTYRENE SULFONATE, which is a drug marketed by Belcher, Chartwell Rx, Citrusphrma, Cmp Pharma Inc, Epic Pharma Llc, Nuvo Pharms Inc, Pai Holdings Pharm, Upsher Smith Labs, Ani Pharms, Hikma, Morton Grove, and Roxane, and is included in twelve NDAs. It is available from nine suppliers. Additional details are available on the SODIUM POLYSTYRENE SULFONATE profile page.

The generic ingredient in SODIUM POLYSTYRENE SULFONATE is sodium polystyrene sulfonate. There are one thousand four hundred and seventy-two drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the sodium polystyrene sulfonate profile page.

Summary for 206815

Tradename:	SODIUM POLYSTYRENE SULFONATE
Applicant:	Chartwell Rx
Ingredient:	sodium polystyrene sulfonate
Patents:	0

Suppliers and Packaging for NDA: 206815

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
SODIUM POLYSTYRENE SULFONATE	sodium polystyrene sulfonate	POWDER;ORAL, RECTAL	206815	ANDA	Chartwell RX, LLC	62135-340	62135-340-11	10 BOTTLE in 1 BOX (62135-340-11) / 15 g in 1 BOTTLE
SODIUM POLYSTYRENE SULFONATE	sodium polystyrene sulfonate	POWDER;ORAL, RECTAL	206815	ANDA	Chartwell RX, LLC	62135-340	62135-340-53	453.6 g in 1 BOTTLE (62135-340-53)

Profile for product number 001

Active Rx/OTC/Discontinued:	RX	Dosage:	POWDER;ORAL, RECTAL			Strength	454GM/BOT
Approval Date:	Feb 18, 2016	TE:	AA	RLD:	No

Complete Access Available with Subscription